Targeted Strategies for Today's Evolving Markets

MissionIR Blog

BioClinica, Inc. (BIOC) Releases OnPoint Platform, Notes Increased Industry Demand

BioClinica, Inc., a global provider of clinical trial management solutions (CTMS), today announced the release of its BioClinica OnPoint platform, which it acquired from TranSenda in 2010.

The company highlighted industry trends migrating toward collaborative technology that can be integrated with existing systems.

“A quiet transformation of clinical study architectures is occurring in the industry through the increased use of standard collaboration tools for clinical study management and regulatory document management,” Gartner Research Vice President Steve Lefebure stated in the press release. “Life science companies are seeking to leverage existing infrastructure, support collaboration, and create flexibility. Solutions that leverage both industry standard collaboration tools and office automation software while providing comprehensive clinical study management capabilities present significant advantages in this environment.”

OnPoint allows sponsors of clinical trials and CROs to access, share and analyze operational trial data using Microsoft® SharePoint standard collaboration and office automation tools. OnPoint’s integration with SharePoint enables users to interact with the system using Microsoft Office applications such as Outlook, Excel and Word. This feature offers organizations lower cost of ownership.

BioClinica also noted increasing demands for CTMS technology and the company’s project pipeline for the current quarter.

“We are experiencing extremely strong interest for OnPoint CTMS,” said Peter Benton, president of eClinical Solutions for BioClinica. “So far in this quarter we have already received contract awards from four pharma and device companies that range from mid to large in size. The combination of features, value and fast implementation – augmented by OnPoint’s out-of-the-box integration with SharePoint – is changing market perceptions of CTMS’ utility and cost-effectiveness.”

For more information visit

Let us hear your thoughts below:

This entry was posted in Small Cap News. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *